natgillin/translations-raw huggingface dataset:
It was centrifuged at 3000 rpm and at 20 °C for 30 min, the liquid separated and the solid (protein mass) suspended over 250.0 mL of acetonitrile. 
To se centrifugira 30 min pri 3000 rpm i pri 20%C, tekući dio se odvoji i krutu tvar (proteinska masa) se suspendira u 250,0 mL acetonitrila.
said new material (18a), (18b), (18c), is submitted to a further step of gluing and/or sewing in parts of tissue, in such a way to be suitable in tailoring to create clothes, tents, accessories, etc. 
- navedeni novi materijal (18a), (18b), (18c) se podvrgava daljnjem stupnju ljepljenja i/ili ušivanja u dijelove tkanine, na takav način da bude prikladan za krojenje u izradi odjeće, zavjesa, dodatnog pribora 1 t.d.
A pharmaceutical composition, comprising 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acceptable excipients, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 6 h to 24 h following administration. 
Farmaceutski sastav za uporabu u liječenju depresije, bolesne potrebe za alkoholom i/ili ovisnosti o alkoholu, predmenstrualne napetosti, predmenstrualnog sindroma ili predmenstrualnog disforičnog poremećaja, naznačen time, da sadrži 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata, kod čega sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 5ng/ml do 500 ng/ml u trajanju od 12 h do 24 h nakon davanja.
represents hydrogen, and 
R* predstavlja vodik, i
The method according to Claim 7, characterized in that said plastic deformation provides a plurality of radial projections (15) arranged in a ring. 
Postupak prema patentnom zahtjevu 6, naznačen time da navedena plastična deformacija osigurava mnoštvo radijalnih izbočenja (15) raspoređenih u prsten.
Compounds according to claim 1, wherein: represents wherein R9 and R9' are as defined in claim 1. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da: predstavlja pri čemu su R9 i R9' definirani u patentnom zahtjevu 1.
A plasterboard panel (1) for access to a compartment comprising: 
Gips kartonska ploča (1) za pristup pretincu, koja obuhvaća:
In some embodiments, the pharmaceutical composition is formulated as a hard or soft capsule, a tablet, a syrup, a suspension, an emulsion, a solution, a solid dispersion, a wafer, or an elixir. 
Farmaceutski pripravak prema zahtjevu 6, naznačen time da je farmaceutski pripravak formuliran kao tvrda ili meka kapsula, tableta, sirup, suspenzija, emulzija, otopina, čvrsta disperzija, wafer, ili eliksir.
The method according to claim 8, wherein the therapy is selected from the group consisting of chemotherapy, monoclonal antibody therapy, surgery, radiotherapy, and photodynamic therapy or a combination thereof. 
Radioimunokonjugat za primjenu u skladu sa zahtjevom 9, naznačen time što je terapija izabrana iz grupe koju čine prijetretman, kemoterapija, terapija monoklonskim antitijelima, kirurška intervencija, radioterapija i/ili fotodinamska terapija.
This invention contemplates the antimicrobial composition for use as a medicament for the treatment of festering wounds, trophic ulcers and burns, infiltrations with marked necrotic and exudative components. 
Sastav prema zahtjevu 1, naznačen time, da služi za uporabu kao lijek za liječenje gnojnih rana, trofičkih čireva i opeklina, infiltracija s naznačenim nekrotičkim i eksudativnim komponentama.
A compound according to claim 7, wherein R1 is (C2-C6)alkenyl, aryl, aryl-S-, heteroaryl or aryl(C1 - C6)alkyl, wherein said aryl or heteroaryl as such or as part of another group is substituted with 1 or 2 substituent(s) R6; 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da R, je (C2-Cg)alkenil, aril, aril-S-, heteroaril ili ari(C,-Cs)alkil, pri čemu je rečeni aril ili heteroaril kao takav ili kao dio druge skupine supstituiran s 1 ili 2 supstituenta Rg;
The AAV vector of any one of claims 1 to 11, wherein the gene encodes the SMN protein and the said subject suffers from spinal muscular atrophy (SMA) disorder. 
AAV vektor iz patentnog zahtjeva 8, pri čemu gen kodira SMN protein 1 poremećaj je spinalna mišićna atrofija (SMA).
Dextromethorphan, administered 15 minutes before GYKI 20039, intraperitoneally, caused a dose-dependent inhibition of the tremor with an ED50 of 24.4 mg/kg. 
Dekstrometorfan, dat intraperitonealno 15 minuta prije GYKI 20039, uzrokuje inhibiciju tremora ovisnu o dozi s EDs9 od 24,4 mg/kg.
at least one water outlet line (18) from said at least one containing means (8) to the at least one downstream industrial process; 
vraćanje filtrirane vode u navedena najmanje jedna sredstva za zadržavanje; korištenje navedene obrađene vode u najmanje jednom nizvodnom industrijskom postupku;
The pharmaceutical composition for use according to any one of claims 1 to 8, wherein the composition further comprises an excipient selected from mannitol, microcrystalline cellulose, crospovidone, and magnesium stearate. 
Farmaceutski pripravak za upotrebu prema zahtjevu 5, naznačen time što pripravak nadalje sadrži pomoću tvar odabranu od manitola, mikrokristalne celuloze, krospovidona, i magnezijevog stearata, ili pri čemu pripravak nadalje sadrži pojačivač permeabilnosti.
An artificial sphincter comprising at least two elements connected to each other and hollow for containing a pressurized fluid; 
Umjetni sfinkter koji sadrži najmanje dva elementa (2) koji su međusobno povezani i šuplji kako bi sadržavali fluid pod tlakom; gdje su navedeni elementi (2) prilagođeni za smještaj na stranama pacijentove mokraćne cijevi;
A T-cell receptor (TCR) which recognises a cell which expresses a polypeptide comprising an amino acid sequence given in any one of Claims 1 to 4, the TCR being obtainable from the cytotoxic T lymphocyte (CTL) of Claim 23, or a functionally equivalent molecule to the TCR. A nucleic acid encoding a T-cell receptor (TCR) according to Claim 24. An expression vector capable of expressing a T-cell receptor (TCR) according to Claim 24. 
Receptor T stanica (TCR) koji prepoznaje stanicu koja abnormalno eksprimira polipeptid sastavljen od aminokiselinskog slijeda spomenutog u bilo kojem od Zahtjeva 1 ili 2, pri čemu je TCR specifičan za peptide iz bilo kojeg Zahtjeva od 1 ili 2 te se može dobiti od citotoksičnih limfocita (CTL-a) iz Zahtjeva 16. Nukleinska kiselina koja kodira receptor T stanica (TCR) prema Zahtjevu 17 ili vektor ekspresije sposoban za ekspresiju spomenutog receptora T stanice (TCR).
a light chain variable region comprising the amino acid sequence of SEQ ID NO:24; 
varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO:24;
The method of clause 57 wherein the licarbazepine acetate is mixed with 20-80 wt% of the total amount of binder. 
Postupak prema zahtjevu 13, naznačen time da se eslikarbazepin acetat miješa s 20-80 tež.% ukupne količine vezivnog sredstva.
A compound according to claim 1 or 2, wherein represents 1,4-phenylene or a group of formula 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što [image] predstavlja 1,4-fenilen ili skupinu formule [image] .
The system of claim 8, wherein the at least two pump segments are configured to be angularly positioned relative to the roller head when the at least two pump segments engage the roller head. 
Sustav prema zahtjevu 6, naznačen time, da su najmanje dva segmenta sisaljke oblikovana za kutni položaj u odnosu na glavu valjka kada su najmanje dva segmenta sisaljke zahvaćena na glavu valjka.
The method according to claim 5, wherein the openings in the upper row are larger than the openings in the lower row. 
Metoda u skladu sa zahtjevom 10, naznačena time da su otvori (144, 145) u gornjem redu (145) veći od otvora u donjem redu (144).
A compound of the general formula (I): wherein, 
PATENTNI ZAHTJEVI Spoj opće formule (I):
is hydrogen, alkyl cycloalkyl, heteroaryl or optionally substituted heteroaryl; 
je vodik, alkil, cikloalkil, heteroaril ili opcijski supstituirani heteroaril;
The anti-Factor D antibody or an antigen-binding fragment thereof of claim 1 comprising a light chain variable domain comprising the amino acid sequence with at least 97% identity to SEQ ID NO:7 and a heavy chain variable domain comprising the amino acid sequence with at least 97% identity to SEQ ID NO:8: 
Protutijelo protiv čimbenika D, ili njegov fragment koji se veže na čimbenik D, u skladu s patentnim zahtjevom 1(ii), naznačeno time što sadrži aminokiselinski slijed varijabilne domene lakog lanca u SEQ ID NO:7, gdje je aminokiselina na položaju 104 u SEQ ID NO:7 valin.
The method according to claim 6, wherein the first groove and the second groove are provided either manually or mechanically using a mountable position adaptor. 
Postupak prema patentnom zahtjevu 9, naznačen time da su fizičke oznake (1, 2) osigurane bilo ručno ili mehanički uporabom ugradivog adaptera pozicije.
The forestry trailer with the mechanism for moving wheel axles according to any of the preceding claims, characterized in that the chassis (1) is made of a one-shaft, two-shaft or more-shaft frame, preferably of a two-shaft frame, wherein the shaft of the frame may have any shape, preferably the shape of a tube. 
Å umarska traktorska prikolica s mehanizmom za premještanje osovina kotača prema bilo kojem od prethodnih zahtjeva, naznačena time, da je šasija (1) načinjena kao jednoosovinski, dvoosovinski ili višeosovinski nosivi okvir, poželjno kao dvoosovinski okvir, pri čemu osovina okvira može imati bilo koji oblik, a poželjno je u obliku cijevi.
A structure of this type allows to provide the sole 211 separately and to apply it subsequently, for example by gluing, to the assembly 212 with the inshoe 227. 
Takva konstrukcija omogućuje odvojenu izradu potplata 211 1 njegovo naknadno postavljanje, na primjer lijepljenjem, na sklop 212 s unutarnjom cipelom 227,
A pharmaceutically acceptable salt according to claim 4, selected from a hydrochloride, a hydrobromide, a sulfate, a nitrate, a phosphate, a metaphosphate, an acetate, a propionate, a hexanoate, a cyclopentanepropionate, a glycolate, a pyruvate, a lactate, a malonate, a succinate, a malate, a maleate, a fumarate, a p-toluenesulfonate, a tartarate, a trifluoroacetate, a citrate, a benzoate, a 3-(4-hydroxybenzoyl)benzoate, a cinnamate, a mandelate, an arylsulfonate, a methanesulfonate, an ethanesulfonate, a 1,2-ethanedisulfonate, a 2-hydroxyethanesulfonate, a benzenesulfonate, a 2-naphthalenesulfonate, a 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylate, a glucoheptonate, a 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylate), a 3-phenylpropionate, a trimethylacetate, a tertiary butylacetate, a lauryl sulfate, a gluconate, a glutamate, a hydroxynaphthoate, a salicylate, a stearate and a muconate. 
Farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 4, naznačena time što je se bira između hidroklorida, hidrobromida, sulfata, nitrata, fosfata, metafosfata, acetata, propionata, heksanoata, ciklopentanpropionata, glikolata, piruvat, laktata, malonata, sukcinata, malata, maleata, fumarata, p-toluensulfonata, tartarata, trifluoracetata, citrata, benzoata, 3-(4-hidroksibenzoil)benzoata, cinamata, mandelata, arilsulfonata, metansulfonata, etansulfonata, 1,2-etandisulfonata, 2-hidroksietansulfonata, benzensulfonata, 2-naftalensulfonata, 4-metilbiciklo[2.2.2]okt-2-en-1-karboksilata, glukoheptonata, 4,4'-metilenbis(3-hidroksi-2-en-1-karboksilata), 3-fenilpropionata, trimetilacetata, tert-butilacetata, lauril-sulfata, glukonata, glutamata, hidroksinaftoata, salicilata, stearata i mukonata.
The anti-CD79b antibody of any one of claims 15 or 19-20, wherein the CD3 binding domain comprises a VL sequence of SEQ ID NO:58. 
Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva 15 ili od 19 do 20, naznačeno time, da domena vezivanja CD3 sadrži VL sekvencu od SEQ ID NO: 58.
The tablet or capsule as defined in any one of claims 1-6, further comprising: from 1% to 2 % by weight of a surfactant. 
Tableta za upotrebu u liječenju tromboembolijskog poremećaja, gdje tableta je tableta kao što je definirano u jednom od patentnih zahtjeva 1 do 5.
In table 11 it is shown that compound (12) is able to decrease the levels of triglycerides in plasma as well as the oxidative stress of those animals. 
U tablici 11 se vidi da spoj (12) može smanjiti razinu triglicerida u plazmi kao također 1 oksidativan stres tih životinja.
Form I of 1-[3-(4-bromo-2-methyl-2 H -pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea in an amount of about 0.01 % to about 5% by weight of the total composition, wherein said Form I is a crystalline form having an X-ray powder diffraction pattern comprising peaks, in terms of 2 θ, at about 5.6 °, about 7.4 °, about 11.2 °, about 21.1 ° and about 25.0 °; 
Oblik I 1-[3-(4-bromo-2-metil-2H-pirazol-3-il)-4-metoksi-fenil]-3-(2,4-difluoro-fenil)-uree u količini od oko 0.01 % do oko 5 masenih % cjelokupnog pripravka, pri čemu navedeni Oblik I je kristalni oblik koji ima uzorak rendgenske difrakcije praha koji obuhvaća vrške, u pogledu 2θ, kod oko 5.6 °, oko 7.4 °, oko 11.2 °, oko 21.1 ° i oko 25.0 °;
The pharmaceutical composition for use according to claim 27, wherein the haematological disease is taken from the list of multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, and acute lymphocytic leukemia. 
Uporaba prema patentnom zahtjevu 16 ili humano antitijelo ili njegov funkcionalni fragment za uporabu prema patentnom zahtjevu 17, pri čemu je hematološka bolest multipli mijelom, kronična limfocitna leukemija, kronična mijelogena leukemija, akutna mijelogena leukemija ili akutna limfocitna leukemija.
reducing Compound 7 to produce Compound 2: 
Postupak dobivanja Spoja 2:
The heating system (100) according to one of the proceedings claims, wherein said primary heating liquid comprises 30-80 vol.-% distilled water, 0,04-0,10 vol.-% Sodium tetraborate Na2B4O7 x 10H2O, 20-65 vol.-% Propylene glycol C3H8O2 or HO-CH2-CHOH-CH3, 0,002-0,025 vol.-% waterglass Na2SiO3, 0,01-0,15 vol.-% Ammonium molybdate (NH4)2MoO4 and 1-3 vol.-% Acetic acid CH3COOH. 
Sustav grijanja (100) u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time što navedena primarna tekućina grijanja sadrži 30-80 vol.% destilirane vode, 0,04-0,10 vol.% natrijevog tetraborata Na»B4O; x 10120, 20 0,15 vol -% amonijevog molibdata (NH,)»MoO, 1 13 vol -% octene kiseline CH2COOH.
The method according to claim 1, wherein said protein is an antibody or a fragment thereof. The method according to claim 11, wherein the antibody is selected from the group consisting of antibodies against ganglioside GD3, antibodies against human interleukin-5 receptor alpha-chain, antibodies against HER2, antibodies against CC chemokine receptor 4, antibodies against CD20, antibodies against CD22, antibodies against neuroblastoma, antibodies against MUC1, antibodies against epidermal growth factor receptor. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što se protutijelo bira iz skupine koju čine protutijela protiv gangliozida GD3, protutijela protiv a-lanca receptora ljudskog interleukina-5, protutijela protiv HER2, protutijela protiv receptora 4 kemokina CC, protutijela protiv CD20, protutijela protiv CD22, protutijela protiv neuroblastoma, protutijela protiv MUC1, protutijela protiv receptora čimbenika rasta epiderme; osobito protutijelo koje se bira iz skupine koju čine Pankomab, Muromomab, Daklizumab, Baziliksimab, Abciksimab, Rituksimab, Herceptin, Gemtuzumab, Alemtuzumab, Ibritumomab, Cetuksimab, Bevacizumab, Tositumomab, Pavlizumab, Infliksimab, Ekulizumab, Epratuzumab, Omalizumab, Efalizumab, Adalimumab, OKT3, protutijelo KM2160 protiv receptora 4 kemokina CC i protutijelo chCE7 protiv neuroblastoma.
A method of preparing a compound of the formula or a pharmaceutically acceptable salt thereof, comprising the steps of: reacting compound 6a: with compound 7a: to form a compound 8a: 
7. Postupak za pripremu spoja formule ili njegove farmaceutski prihvatljive soli, koji sadrži korake: i) reagiranja spoja 6: sa spojem 7a: da se formira spoj &a:
In a particularly preferred manner, the hydrocarbon source is chosen from the group consisting of ethane, propane and propane/butane mixtures. 
Postupak prema bilo kojem zahtjevu 1 i 2, naznačen time da je izvor ugljikovodika odabran iz skupine koja se sastoji od etana, propana, butana i mješavina propana/butana.
The T cell activating bispecific antigen binding molecule of any one of the preceding claims, wherein the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain. 
dvostruko specifična vezivna molekula antigena za aktivaciju T stanice je definirana u patentom zahtjevu 5(i) te pri čemu su druga i treća antigen-vezivna polovica i Fc domena dio imunoglobulinske molekule, osobito IgG razreda imunoglobulina;
A compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein 
Spoj s formulom (I) [image] ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf, naznačen time da
The composition of item 33, wherein the cationic lipid is 5 to 40 mol % of the lipid molecules. 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što je kationski lipid 5 do 40 mol % molekula lipida.
The present investigators have found that typically 2 to 5 mL of the hydrogel are suitable to provide adequate resistance in the urethra by bulking the urethra. 
Dosadašnji istraživači su našli da je tipično 2 do 5 ml hidrogela prikladno za osiguravanje odgovarajuće otpornosti u mokraćnoj cijevi povećavajući volumen mokraćne cijevi.
The "HIP/PAP" protein or a protein derivative thereof for use in preventing or treating a neonatal brain injury, which includes a neonatal brain injury caused by a brain hypoxia, wherein the "HIP/PAP" protein comprises an amino acid sequence having at least 90% amino acid identity with a polypeptide selected from the group consisting of the polypeptides of SEQ ID NO 1 to 3, wherein the protein derivative thereof is selected from the group consisting of a biologically active portion of a "HIP/PAP" protein and "HIP/PAP" chimeric or fusion proteins, and wherein the said neonatal brain injury encompasses a pathological state selected from the group consisting of foetal hypoxemia, perinatal hypoxemia, foetal ischemia, perinatal ischemia, and an excess release of excitatory neurotransmitters. 
HR P20180090 T1 PATENTNI ZAHTJEVI "HIP/PAP" protein ili njegov derivat proteina za uporabu u prevenciji ili liječenju neonatalne ozljede mozga, koja uključuje neonatalnu ozljedu mozga uzrokovanu hipoksijom mozga, pri čemu "HIP/PAP" protein sadrži sekvencu aminokiseline koja ima barem 90% identičnosti aminokiseline s polipeptidom odabranim iz skupine koju čine polipeptidi sa SEQ ID NO 1 do 3, pri čemu je njegov derivat proteina odabran iz skupine koja se sastoji od biološki aktivnog dijela "HIP/PAP" proteina i "HIP/PAP" kimernih ili fuzijskih proteina, i pri čemu navedena neonatalna ozljeda mozga obuhvaća patološko stanje odabrano iz skupine koja se sastoji od fetalne hipoksemije, perinatalne hipoksemije, fetalne ishemije, perinatalne ishemije, te suvišnog otpuštanja ekscitacijskih neurotransmitera.
Another embodiment of the method according to the invention is a method for producing a low fat spread comprising 20-60% fat and 2-5% whey protein, said method comprising the following steps: preparing an aqueous solution of 3 to 10% whey proteins, a pH value of about 7-9, wherein the calcium concentration has been reduced by at least about 50% (1 mM calcium or less), more preferably by at least about 95%. heating the solution resulting from step (i) to a temperature of about 50 to 100° C. in 0.15 to 30 minutes; 
Postupak prema bilo kojem od zahtjeva 1-7, kojim se proizvodi namaz s niskim sadržajem masti sadrži 20-60% masti 1 2-5% proteina sirutke, taj postupak obuhvaća sljedeće korake: (i) pripremu vodene otopine koja sadrži 3 do 10% proteina sirutke, ima pH vrijednost od 7 do 9, a koncentracija kalcija u proteinu sirutke iznosi 1.4 mM ili manje ili je smanjena za barem 50%; (1i) zagrijavanje otopine dobivene u koraku (1) do temperature od 50 do 100%C kroz 0.15 do 30 minuta;
A data management system for interactive digital cinema, comprising input means for collecting digital data from members of an audience and processing means for processing said data characterized in that said data management system further comprises a digital content interface for interfacing said processed data with a digital content server providing interactive content to said audience. 
Sustav za upravljanje podacima koji omogućava povezivanje između sustava reakcije publike i poslužitelja digitalnih sadržaja, koji poslužitelji digitalnog sadržaja se koristi za upravljanje interaktivnih digitalnih kina i kontrolira digitalni projektor za projiciranje sadržaja na ekranu, koji navedeni sustav upravljanja podacima sadrži:
NMR=nuclear magnetic resonance 
NMR = nuklerana magnetna rezonanca
Breast cancer, colorectal cancer or renal cell carcinoma. 
Rak dojke, kolorektalni karcinom ili karcinom bubrežnih stanica
The method according to paragraph 1, wherein the L1 signaling information has data slice ID information that identifies the data slice. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu informacija signaliziranja L1 ima ID informaciju podatkovnog Teza koja identificira podatkovni rez.
The method of claim 17, wherein the endoparasitic infection is caused by a helminth selected from the group consisting of Anoplocephala, Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocyclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Triodontophorous, Uncinaria, Wuchereria, and combinations thereof. 
HR P20190408 T1 se prenose helmintima odabranima iz skupine koja se sastoji od sljedećih: Anaplocephala (Anoplocephala), Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocyclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Triodontophorus, Uncinaria, Wuchereria i njihove kombinacije.
The immunoconjugate of claim 3, wherein said modification is a knob-into-hole modification, comprising a knob modification in one of the two subunits of the Fc domain and a hole modification in the other one of the two subunits of the Fc domain, wherein said knob modification comprises the amino acid substitution T366W, and said hole modification comprises the amino acid substitutions T366S, L368A and Y407V (EU numbering). 
Imunokonjugat u skladu s patentnim zahtjevom 3, naznačen time, da je navedena modifikacija modifikacija drške-u-šupljinu, koja obuhvaća modifikaciju drške u jednoj od dviju podjedinica Fc domene 1 modifikaciju šupljine u drugoj od dviju podjedinica Fc domene, pri čemu navedena modifikacija drške obuhvaća aminokiselinsku supstituciju T366W, a navedena modifikacija šupljine obuhvaća aminokiselinske supstitucije T366$, L368A i Y407V (EU numeracija).
The process of claim 1, wherein step (1x) further comprises the conversion of the ester of formula (1e) to compound (X), by 
Postupak prema zahtjevu 1, gdje korak (1x) dalje sadrži konverziju estera formule (1e) do spoja (X), pomoću g